By Euronews
Published on
Share this article
Comments
$11.8 billion is the price Nestle is going to pay for US firm Pfizer’s infant nutrition business . That is about two billion more than the maximum expected by investors.
In Behind Markets we look at the reasons for the high price and the effects it had.
Click on the link above to see the report
Share this article
Comments
